Finance

Lists
Why is OMDA down 2,56%?
Dive Deeper
OMDA:NASDAQ
Omada Health Inc
13,72 USD
-2,56%
(-0,36) 1D
18-ноя., 11:23:38 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for OMDA...
Open
13,99 USD
High
14,41 USD
Low
13,52 USD
Mkt. cap
851,16 млн
Avg. vol.
1,28 млн
Volume
137,54 миң
P/E ratio
62,79
52-wk high
25,44 USD
52-wk low
10,28 USD
EPS
0,22 USD
Shares outstanding
62,04 млн
No. of employees
980
Open
13,99 USD
High
14,41 USD
Low
13,52 USD
Mkt. cap
851,16 млн
Avg. vol.
1,28 млн
Volume
137,54 миң
P/E ratio
62,79
52-wk high
25,44 USD
52-wk low
10,28 USD
EPS
0,22 USD
Shares outstanding
62,04 млн
No. of employees
980
News stories
From web sources and news partners
About Omada Health Inc
CEO-
Employees980
Founded2011
HeadquartersЮг Сан Франциско, Калифорния, Америка Кошмо Штаттары
SectorHealth Care
IndustryHealth care provider
Analyst ratings
Based on 10 analysts giving stock ratings to OMDA in the past 3 months
Strong buy
Buy
9
Hold
1
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for OMDA in the last 3 months.
Highest
Current 13,72 USD
35,00 USD (+155,10%)
Average
27,10 USD (+97,52%)
Lowest
19,00 USD (+38,48%)
Analyst
Recommendation
Action
Price target
Projected
Date
Lisa Gill
J.P. Morgan
Buy
Reiterated
25,00 USD
+82,2%
11/16/2026
Craig Hettenbach
Morgan Stanley
Buy
Reiterated
30,00 USD
+118,7%
11/09/2026
Richard Close
Canaccord Genuity
Buy
Reiterated
28,00 USD
+104,1%
11/06/2026
Sean Dodge
BMO Capital
Buy
Maintained
24,00 USD
+74,9%
11/05/2026
Stan Berenshteyn
Wells Fargo
Hold
Maintained
19,00 USD
+38,5%
11/05/2026
David Larsen
BTIG
Buy
Reiterated
35,00 USD
+155,1%
11/05/2026
Saket Kalia
Barclays
Buy
Maintained
22,00 USD
+60,3%
11/06/2026
Eugene Mannheimer
Freedom Capital Markets
Buy
Reiterated
35,00 USD
+155,1%
09/14/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
25,00 USD
+82,2%
09/11/2026
Ryan MacDonald
Needham
Buy
Reiterated
28,00 USD
+104,1%
09/11/2026
Constantine Davides
Citizens JMP
Buy
Maintained
27,00 USD
+96,8%
07/20/2026
David Roman
Goldman Sachs
Buy
Maintained
25,00 USD
+82,2%
06/10/2026
Last report
2026-ж., 5-ноя.
Fiscal period
Q3 2026
0,21 USD / 0,10 USD
+114,27%beat
Revenue / Est. (USD)
91,31 млн / 85,64 млн
+6,62%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
75,85 млн
78,05 млн
87,84 млн
91,31 млн
Cost of goods sold
22,18 млн
29,36 млн
24,05 млн
22,02 млн
Cost of revenue
22,18 млн
29,36 млн
24,05 млн
22,02 млн
Research and development expenses
11,55 млн
12,70 млн
14,62 млн
15,27 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
38,83 млн
40,78 млн
45,61 млн
49,19 млн
Operating expense
50,38 млн
53,47 млн
60,24 млн
64,46 млн
Total operating expenses
72,56 млн
82,83 млн
84,29 млн
86,49 млн
Operating income
3,28 млн
-4,78 млн
3,55 млн
4,82 млн
Other non operating income
-
-
-
-
EBT including unusual items
5,16 млн
-2,97 млн
5,29 млн
6,55 млн
EBT excluding unusual items
5,16 млн
-2,97 млн
5,29 млн
6,55 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
5,16 млн
-2,97 млн
5,29 млн
6,55 млн
Net profit margin
6,80%
-3,81%
6,03%
7,17%
Earnings per share
0,16
0,05
0,20
0,21
Interest and investment income
1,89 млн
1,83 млн
1,76 млн
1,99 млн
Interest expense
-13,00 миң
-18,00 миң
-14,00 миң
-262,00 миң
Net interest expenses
1,88 млн
1,81 млн
1,74 млн
1,73 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
4,73 млн
-3,27 млн
5,13 млн
6,50 млн
Gain or loss from assets sale
6,00 миң
2,00 миң
25,00 миң
27,00 миң
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору